Actively Recruiting
Evaluating the Safety and Effectiveness of PT027 Compared to PT007 Inhalers as Needed in Symptomatic Chinese Adults with Asthma
Led by AstraZeneca · Updated on 2026-09-21
1000
Participants Needed
102
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of a combination budesonide and albuterol metered dose inhaler BDA MDI compared with an albuterol sulfate AS metered dose inhaler in symptomatic Chinese adults with asthma. This randomized, double-blind, Phase III study aims to reduce the risk of severe asthma exacerbations in participants who have had asthma diagnosed for at least 12 months and currently use maintenance therapies. The study involves about 1000 eligible participants randomly assigned to receive either BDA MDI 160180 mcg delivered as two actuations of 8090 mcg or AS MDI 180 mcg delivered as two actuations of 90 mcg. Both treatments are used as needed for asthma symptoms or before exercise. The trial includes a screening period lasting 14 to 28 days, followed by a treatment period of at least 24 weeks and up to 52 weeks, and concludes with a safety follow-up about two weeks after the last treatment visit. Participants will be assessed through various visits during the study, including evaluations of lung function, asthma control questionnaires ACQ-5 and ACQ-7, and monitoring of severe asthma exacerbations. The primary outcome is the time to the first severe asthma exacerbation over the treatment period. Secondary outcomes include the rate of exacerbations, steroid exposure, and patient-reported measures of asthma control and quality of life. Safety and adherence are closely monitored throughout the study duration.
CONDITIONS
Brief Title
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here